Year-to-date revenue growth had support from healthy same-facility growth as an increase in total joint replacements boosted surgical case volumes. We expect Surgery Partners to grow its revenue over 12% in 2024 and over 8% in 2025 and maintain its EBITDA margin at about 15% through 2025. The company continues to benefit from a favorable mix of higher-acuity musculoskeletal surgical procedures and pain management that result in a higher EBITDA margin than peers. Additionally, with moderating wage inflation, the company will likely maintain or expand its EBITDA as it grows, which will drive incremental cash flow generation. Further, we expect the company can recruit and retain physicians to augment its revenue growth by targeting higher acuity specialists. The increasing popularity
